(Q43597808)

25 November 2017

title

Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

metastatic colon cancer

1 reference

inferred from title

author

François Ghiringhelli

1

object named as

François Ghiringhelli

0 references

Bruno Chauffert

4

object named as

Bruno Chauffert

0 references

author name string

François Ghiringhelli

1

1 reference

25 November 2017

Julie Vincent

2

1 reference

25 November 2017

Boris Guiu

3

1 reference

25 November 2017

Bruno Chauffert

4

1 reference

25 November 2017

Sylvain Ladoire

5

1 reference

25 November 2017

publication date

6 November 2010

1 reference

Investigational New Drugs

25 November 2017

published in

1 reference

25 November 2017

volume

30

1 reference

25 November 2017

issue

2

1 reference

25 November 2017

page(s)

758-764

1 reference

Global cancer statistics, 2002

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Treatment of colorectal liver metastases: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Abdominal fat: standardized technique for measurement at CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9575-3

Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer

21 January 2018

1 reference

12 December 2020

The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer

1 reference

12 December 2020

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

12 December 2020

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

1 reference

12 December 2020

10.1007/S10637-010-9575-3

Identifiers

DOI

1 reference

Dimensions Publication ID

25 November 2017

1025259367

0 references

1 reference